TREA

88339989 - DIAFERT

Follow

Information

  • Trademark
  • 88339989
  • Serial Number
    88339989
  • Filing Date
    March 14, 2019
    5 years ago
  • Transaction Date
    August 17, 2020
    4 years ago
  • Status Date
    August 17, 2020
    4 years ago
  • Location Date
    August 17, 2020
    4 years ago
  • Status Code
    602
  • Current Location
    TMO LAW OFFICE 115 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    CHANG, KATHERINE S
  • Attorney Name
    Matthew O. Brady
    Law Office Assigned Location Code
    M60
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
DIAFERT
Case File Statements
  • GS0051: Pharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma agents and decongestants; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular diseases and high blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations for supporting, encouraging and promoting bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals; antiprotozoans, namely, pharmaceutical preparations for treating infections caused by protozoa; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS (central nervous system) disorders, neurological disorders, neurodegenerative disorders and depression; neuroprotective agent, namely, pharmaceutical preparations to help prevent or reduce damage to the brain or spinal cord; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents, namely, pharmaceutical preparations for dilating blood vessels; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenating creams, rehydrating creams and lotions for the face and body, excluding iron preparations for pharmaceutical use and iron preparations as food supplements
Case File Event Statements
  • 8/17/2020 - 4 years ago
    21 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2
  • 8/17/2020 - 4 years ago
    20 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 2/4/2020 - 4 years ago
    19 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 2/4/2020 - 4 years ago
    18 - FINAL REFUSAL E-MAILED Type: GNFR
  • 2/4/2020 - 4 years ago
    17 - FINAL REFUSAL WRITTEN Type: CNFR
  • 1/13/2020 - 4 years ago
    16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/13/2020 - 4 years ago
    15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/9/2020 - 4 years ago
    14 - ASSIGNED TO LIE Type: ALIE
  • 12/17/2019 - 4 years ago
    13 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/13/2019 - 4 years ago
    12 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 12/13/2019 - 4 years ago
    11 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 12/13/2019 - 4 years ago
    10 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/21/2019 - 4 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/21/2019 - 4 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/21/2019 - 4 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/29/2019 - 5 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/29/2019 - 5 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/29/2019 - 5 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/23/2019 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/2/2019 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 3/18/2019 - 5 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP